News

People with primary Sjögren’s disease, particularly those with more severe illness, show significantly different patterns of alternative splicing — a process in which cells mix and match gene instructions to create different versions of a protein — in 10 genes compared with healthy people, according to a study in China.

Initial data from an early clinical trial testing CLN-978, Cullinan Therapeutics’ experimental therapy, in adults with moderate to severe Sjögren’s disease are expected in the final months of the year. The announcement was part of a company press release providing the latest financial results and corporate updates.

Adults with primary Sjögren’s disease are at a higher risk of developing colorectal and pancreatic cancers — especially women and older patients — according to a Korean study. “Further research should explore the underlying mechanisms and the impact of [primary Sjögren’s disease] duration and severity on cancer risk,” researchers…

People living with Sjögren’s disease often experience disabling symptoms that have a substantial impact on day-to-day life, even as they face dismissal from healthcare providers and judgment from peers, a new review study reports. Based on the findings, scientists are calling for greater efforts to support people with Sjögren’s,…

The “Sjögren’s protein score,” a newly identified blood protein signature of Sjögren’s disease, may help doctors measure inflammation inside the salivary glands without the need for a biopsy, a new study suggests. Results from the blood test, based on a group of 16 immune-related proteins, reflected local glandular…

A computer-based gene activity analysis combined with artificial intelligence (AI) methods has identified a dozen potential biomarkers that may ultimately help clinicians in reaching a Sjögren’s disease diagnosis more quickly, according to researchers in China. Their study found that activity levels of these new biomarkers were significantly associated with…

Stellular Bio has raised early-stage investment to advance its treatment candidate, STLR-201, into clinical testing as a potential off-the-shelf therapeutic option for dry eye caused by Sjögren’s disease. Part of a therapy class called platelet-derived regenerative biologics (PRBs), STLR-201 is derived from stem cells that can produce platelets,…

A new publicly available artificial intelligence (AI) tool that analyzes results from routine laboratory blood tests may improve the diagnosis of Sjögren’s disease, according to a multicenter study in China. The AI system, called Sjogren Multi-criterion Feature Integration Framework (SMFIF), distinguished people with Sjögren’s from those with Sjögren’s-like…

Ianalumab, an experimental treatment for Sjögren’s disease from Novartis, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA). The FDA gives this designation to experimental therapies that have the potential to address unmet needs in the care of serious diseases, with the goal…

Primary Sjögren’s disease may be divided into two main clinical subtypes, according to a recent study that used artificial intelligence. “Our study suggests that primary Sjögren’s syndrome consists of distinct clinical subtypes with different organ involvement patterns and immunological features,” the researchers wrote. “The data-driven classification system complements traditional…